SELLAS Life Sciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
SELLAS Life Sciences (NASDAQ:SLS) announced that President and CEO Angelos Stergiou will present at three investor events in May 2026 focused on oncology and healthcare.
Appearances include the 2026 Stifel Virtual Targeted Oncology Forum, A.G.P.'s Annual Virtual Healthcare Conference, and TD Cowen’s 7th Annual Oncology Innovation Summit.
Positive
- None.
Negative
- None.
News Market Reaction – SLS
In the May 14 session, SLS gained 13.63%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.6% during that session. Our momentum scanner triggered 59 alerts that day, indicating high trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences:
2026 Stifel Virtual Targeted Oncology Forum
Format: Corporate Presentation and Fireside Chat
Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET
Location: New York, NY
Webcast Link: Click here
A.G.P.'s Annual Virtual Healthcare Conference
Format: Fireside Chat
Date: Wednesday, May 20, 2026, at 11:00 AM ET
Location: Virtual
Webcast Link: Click here
TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Format: Fireside Chat
Date: Wednesday, May 27, 2026, at 9:00 AM ET
Location: Virtual
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
